Home  |  Contact

Cellosaurus U266/ADM (CVCL_GZ72)

[Text version]

Cell line name U266/ADM
Accession CVCL_GZ72
Resource Identification Initiative To cite this cell line use: U266/ADM (RRID:CVCL_GZ72)
Comments Characteristics: Produces IgE lambda.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for BRAF p.Lys601Asn (c.1803A>T) (from parent cell line).
Heterozygous for MSH6 p.Gly141Asp (c.422G>A) (from parent cell line).
Homozygous for TP53 p.Ala161Thr (c.481G>A) (ClinVar=VCV000161518) (from parent cell line).
Homozygous for TRAF3 p.Lys550Leufs*3 (c.1648_1649insT) (from parent cell line).
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0566 (U266B1)
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line
Publications

PubMed=26045737
Xu P., Jiang Y.-F., Wang J.-H.
shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Int. J. Clin. Exp. Pathol. 8:2300-2310(2015)

Cross-references
Other Wikidata; Q54973632
Entry history
Entry creation26-Sep-2016
Last entry update02-Jul-2020
Version number7